- Home
- NDLS vs VYNE Comparison
NDLS vs VYNE Comparison
Compare NDLS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- VYNE
- Stock Information
- Founded
- NDLS 1995
- VYNE 2003
- Country
- NDLS United States
- VYNE United States
- Employees
- NDLS N/A
- VYNE N/A
- Industry
- NDLS Restaurants
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- VYNE Health Care
- Exchange
- NDLS Nasdaq
- VYNE Nasdaq
- Market Cap
- NDLS 34.3M
- VYNE 35.7M
- IPO Year
- NDLS 2013
- VYNE 2018
- Fundamental
- Price
- NDLS $1.18
- VYNE $1.64
- Analyst Decision
- NDLS Strong Buy
- VYNE Strong Buy
- Analyst Count
- NDLS 2
- VYNE 2
- Target Price
- NDLS $3.00
- VYNE $6.88
- AVG Volume (30 Days)
- NDLS 122.1K
- VYNE 199.7K
- Earning Date
- NDLS 03-06-2025
- VYNE 03-06-2025
- Dividend Yield
- NDLS N/A
- VYNE N/A
- EPS Growth
- NDLS N/A
- VYNE N/A
- EPS
- NDLS N/A
- VYNE N/A
- Revenue
- NDLS $493,271,000.00
- VYNE $501,000.00
- Revenue This Year
- NDLS $4.73
- VYNE N/A
- Revenue Next Year
- NDLS $1.30
- VYNE $20.00
- P/E Ratio
- NDLS N/A
- VYNE N/A
- Revenue Growth
- NDLS N/A
- VYNE 18.16
- 52 Week Low
- NDLS $0.55
- VYNE $1.53
- 52 Week High
- NDLS $2.36
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- NDLS 48.32
- VYNE 34.09
- Support Level
- NDLS $1.01
- VYNE $1.53
- Resistance Level
- NDLS $1.20
- VYNE $1.86
- Average True Range (ATR)
- NDLS 0.08
- VYNE 0.16
- MACD
- NDLS 0.00
- VYNE 0.00
- Stochastic Oscillator
- NDLS 89.47
- VYNE 24.44
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.